VolitionRx (VNRX) Form 4: CEO Reynolds purchases 15,000 shares

Rhea-AI Filing Summary

Cameron John Reynolds, President and CEO and a director of VolitionRx Ltd (VNRX), reported an open-market purchase of common stock on 09/12/2025. He acquired 15,000 shares at $0.659 per share. After the transaction he directly beneficially owns 2,624,847 shares and indirectly owns 1,007,718 shares through Concord International, Inc.; an additional 34,076 shares are held indirectly by his spouse.

The Form 4 is signed on 09/15/2025. The filing notes Reynolds is majority shareholder of Concord International, Inc., sharing voting and dispositive control over those shares.

Positive

• Insider purchase disclosed: 15,000 shares acquired on 09/12/2025 at $0.659 demonstrates insider buying activity.
• Clear ownership disclosure: Identifies direct holdings (2,624,847), indirect holdings via Concord International, Inc. (1,007,718), and spouse (34,076).
• Filing completeness: Form 4 is signed and dated (09/15/2025) and states the reporting person’s roles (President, CEO, Director).

Negative

• None.

Insights

Securities Analyst

TL;DR: Insider purchased a modest amount of shares, increasing direct holdings; transaction is informational but not clearly material to valuation.

The purchase of 15,000 shares at $0.659 is a routine insider buy disclosed under Section 16. The transaction increases Mr. Reynolds's direct stake to 2.62 million shares while substantial indirect holdings remain via Concord International, Inc. and a spouse. The absolute size of the purchase is small relative to his total holdings, so the filing signals insider participation but is unlikely to be materially value-driving on its own.

Corporate Governance Expert

TL;DR: Reporting is complete and compliant; control relationships are disclosed clearly.

The Form 4 discloses the reporting person's roles as President, CEO and director and clarifies indirect ownership through Concord International, Inc. and a spouse, satisfying transparency expectations for related-party control and voting authority. The filing is signed and dated properly, with no amendments indicated. From a governance perspective, disclosure quality is adequate.

Insider Trade Summary

Net Buyer: 15,000 shares ($9,885)

Net Buy 3 txns

Insider Reynolds Cameron John

Role President and CEO

Bought 15,000 shs ($10K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	15,000	$0.659	$10K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 2,624,847 shares (Direct); Common Stock — 1,007,718 shares (Indirect, By Concord International, Inc.)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Reynolds Cameron John

(Last) (First) (Middle)

1489 WEST WARM SPRINGS ROAD

SUITE 110

(Street)

HENDERSON NV 89014

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VOLITIONRX LTD [ VNRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
09/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/12/2025		P		15,000	A	$0.659	2,624,847	D
Common Stock								1,007,718	I	By Concord International, Inc.(1)
Common Stock								34,076	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares of common stock are held directly by Concord International, Inc. Mr. Reynolds is the majority shareholder of Concord International, Inc. and shares voting and dispositive control over the shares of common stock held by Concord International, Inc.

Remarks:

	/s/ Cameron John Reynolds	09/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Cameron John Reynolds report on Form 4 for VNRX?

He reported an open-market purchase of 15,000 common shares on 09/12/2025 at $0.659 per share, with the Form 4 signed 09/15/2025.

How many VNRX shares does Reynolds own after the transaction?

Directly owns 2,624,847 shares; additionally 1,007,718 shares indirectly via Concord International, Inc. and 34,076 shares via spouse.

What is the relationship between Reynolds and Concord International, Inc.?

Reynolds is the majority shareholder of Concord International, Inc. and shares voting and dispositive control over the shares it holds.

Does the Form 4 indicate any derivative transactions?

No. The filing contains entries only in Table I for non-derivative common stock; Table II shows no derivative transactions.

What roles does the reporting person hold at VolitionRx Ltd?

He is listed as President, CEO and a Director on the Form 4.